1.
Pharmacokinetics of intravitreal ranibizumab (Lucentis).
Bakri Sophie J, Snyder Melissa R, Reid Joel M, Pulido Jose S, Ezzat Mohamed K, Singh Ravinder J
OphthalmologyDec 2007437 citationsBasic Science
This rabbit study found intravitreal ranibizumab has a 2.88-day vitreous half-life, shorter than bevacizumab, with no systemic or fellow-eye detection, suggesting a favorable safety profile.